Mannitol inhalation - Pharmaxis

Drug Profile

Mannitol inhalation - Pharmaxis

Alternative Names: Bronchitol; Mannitol dry powder for inhalation - Pharmaxis; Precision spray‐dried mannitol

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Royal Prince Alfred Hospital
  • Developer Pharmaxis
  • Class Small molecules; Sugar alcohols
  • Mechanism of Action Osmotic diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Bronchiectasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchiectasis; Cystic fibrosis

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase III Bronchiectasis
  • Discontinued Allergic rhinitis; Sinusitis

Most Recent Events

  • 27 Sep 2016 Registered for Cystic fibrosis in Russia (Inhalation)
  • 16 Dec 2015 Efficacy and adverse events data from a phase II trial in cystic fibrosis released by Pharmaxis
  • 08 May 2015 Mannitol inhalation licensed to Chiesi Farmaceutici in Germany, Ireland and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top